Key Highlights

  • Net loss was USD 3.5 million, or USD 1.98 per share, in the third quarter.
  • Research and development rose to USD 1.7 million from USD 634 thousand.
  • Selling, general and administrative expense fell to USD 1.8 million from USD 2.7 million.
  • Nine-month net loss was USD 10.9 million versus USD 22.6 million.

Research Spending Rises, Administrative Costs Fall

GT Biopharma, Inc. (NASDAQ:GTBP) reported a third-quarter loss from operations of USD 3.5 million versus USD 3.4 million a year earlier. Research and Development expense rose to USD 1.7 million from USD 634 thousand, while selling, general and administrative expense fell to USD 1.8 million from USD 2.7 million. The data set carried an estimated loss of USD 2.50 per share and no actual figure, so the filing results are used.

Net loss was USD 3.5 million, and after a preferred Dividend of USD 52 thousand the loss attributable to common stockholders was USD 3.6 million, or USD 1.98 per share on 1.8 million weighted average shares. In the prior-year quarter the company reported Net Income of USD 8.3 million, driven by a USD 11.4 million favorable change in the Fair Value of a Greenshoe Rights liability.

Nine-Month Results

For the nine months, research and development was USD 3.2 million versus USD 2.1 million and selling, general and administrative expense was USD 7.7 million versus USD 4.7 million. Loss from operations was USD 10.9 million versus USD 6.8 million, and interest expense was USD 190 thousand versus none.

Net loss was USD 10.9 million, compared with USD 22.6 million a year earlier, when the company recorded a USD 28.7 million loss on initial recognition of the Greenshoe Rights liability. Net loss attributable to common stockholders was USD 11.5 million, or USD 7.61 per share, versus USD 26.9 million, or USD 222.58.

Weighted average common shares were 1.8 million for the quarter versus 157,629 a year earlier, and 1.5 million for the nine months versus 121,001. Preferred dividends were USD 229 thousand for the nine months, a deemed dividend of USD 433 thousand was recorded, and interest income was USD 164 thousand versus USD 106 thousand.

Company Profile and Going Concern Note

The company describes itself as a "clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products" built on its TriKE and Dual Targeting TriKE immune cell engager platforms.

The filing notes that the company's independent registered public accounting firm, in its report on the December 31, 2025 financial statements, raised substantial doubt about the company's ability to continue as a going concern. During the quarter the company converted Series C and Series L convertible preferred stock into common shares and issued common stock in settlement of a vendor payable.

Metrics to Track

Reference points include quarterly research spending as clinical work advances, general and administrative levels after the nine-month increase, preferred stock conversions and the cash runway described in the Liquidity section of the filing.